ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

New Rheumatology Disease Research & Advice

Thomas R. Collins  |  February 17, 2018

SAN DIEGO—Top researchers gathered for a review course at the start of the 2017 ACR/ARHP Annual Meeting in November to describe new research, their own treatment strategies and new ways of thinking about an array of rheumatic diseases. Here are the highlights: Raynaud’s & Other Digit Problems When a patient walks into your clinic with…

Filed under:Axial SpondyloarthritisMeeting ReportsOsteoarthritis and Bone DisordersRheumatoid ArthritisSystemic SclerosisVasculitis Tagged with:ACR/ARHP Annual Meetingadhesive capsulitisANCAaxial spondyloarthritis (SpA)diabetesDry eyeEthicslung diseasemeniscus surgeryOsteoarthritisRaynaud'sred eyeRheumatoid arthritisscleritisVasculitis

Recognizing Physician Burnout, & Tips to Fight It

Philip Seo, MD, MHS  |  February 17, 2018

4 Patients in 4 Weeks Baltimore is a little over two hours away from Richmond, Va., by car. I know this now because I recently drove to Richmond to attend a memorial service. I drove in silence. Music made me sleepy, and I could not bear to listen to another iteration of how we are…

Filed under:OpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:physician burnout

Diffuse Scleroderma: A 1991 Case Through the Lens of Today

Diffuse Scleroderma: A 1991 Case Through the Lens of Today

Charles Radis, DO  |  February 17, 2018

The year was 1991. It was my first Tuesday as a rheumatology fellow at the University of Pittsburgh’s Presbyterian Hospital. Navigating a maze of buildings and hallways, I delivered myself to the entrance to the scleroderma clinic. Running late and not knowing whether there was a separate entrance for staff, I clicked open the door….

Filed under:ConditionsSystemic Sclerosis Tagged with:case reportScleroderma

Etanercept Biosimilar Is Effective, Well-Tolerated for Rheumatoid Arthritis

David Douglas  |  February 16, 2018

NEW YORK (Reuters Health)—The biosimilar LBEC0101 is equivalent to etanercept (Enbrel) in treating patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate, according to researchers from Korea and Japan. As Dr. Yeong-Wook Song tells Reuters Health by email, “LBEC0101 is comparable in efficacy, safety and immunogenicity profile to Enbrel.” The findings, he adds, could…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsetanerceptLBEC0101Rheumatoid Arthritis (RA)

Persistent Pain Merits Better Access to Psychosocial Care, Group Says

Will Boggs MD  |  February 14, 2018

NEW YORK (Reuters Health)—People with persistent pain need better access to psychosocial care, according to a position statement from the Society of Behavioral Medicine (SBM). “Psychosocial approaches to pain management need to be available for all individuals with persistent pain in all healthcare settings,” Dr. E. Amy Janke from the University of the Sciences, in…

Filed under:Conditions Tagged with:persistent painSociety of Behavioral Medicine (SBM)

FDA Receives Reports of Loperamide Abuse

Michele B. Kaufman, PharmD, BCGP  |  February 14, 2018

The FDA is seeking to limit the number of loperamide doses per package due to reports of heart-related problems and death from the misuse and abuse of the treatment…

Filed under:Drug Updates Tagged with:abuseDrug SafetyFDAloperamideSafetyU.S. Food and Drug Administration (FDA)

Rheumatologist Shortage Looms Amid Surging Patient Demand

Lisa Rapaport  |  February 8, 2018

(Reuters Health)—A growing number of patients are seeking care from rheumatologists for chronic health problems like arthritis, back pain and osteoporosis, just as the supply of specialists is shrinking, two new studies suggest. An estimated 6,013 clinicians in the U.S. specialized in rheumatology as of 2015, the equivalent of 5,415 full-time providers, according to one…

Filed under:Practice SupportWorkforce Tagged with:rheumatologist shortagesurging patient demandworkforce shortage

EU Approves Marketing for Ixekizumab in Adults with PsA

Michele B. Kaufman, PharmD, BCGP  |  February 7, 2018

In its second indication in the EU, ixekizumab has been approved by the European Commission to treat adults with active psoriatic arthritis…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:EuropeEuropean Unionixekizumabpsoriatic arthritisskin

Arthritis Crisis: It’s Time to Act

Susan Bernstein  |  February 5, 2018

Funding drives arthritis research breakthroughs and prevention programs, and advocates from the ACR, Arthritis Foundation and the National Recreation and Park Association (NRPA) pitched funding increases to lawmakers at a lunchtime briefing held Feb. 1 in Washington, D.C., in cooperation with the Congressional Arthritis Caucus. During the briefing, titled $300 Billion Crisis: The High Cost…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Arthritis 101Arthritis FoundationCongressional Arthritis CaNational Recreation and Park Asso

ACGME Milestones Debated at ACR: Does the Milestones System Ask too many Questions?

Larry Beresford  |  February 5, 2018

Milestones are at the core of the current system designed to evaluate medical residency and fellowship programs and their participants. But are all milestones meaningful for medical education? This idea was at the center of a debate during the 2017 ACR/ARHP Annual Meeting, during which speakers explored the advantages and drawbacks of using training milestones for rheumatology fellowships…

Filed under:Education & TrainingProfessional Topics Tagged with:2017 ACR/ARHP Annual MeetingACGMEACR/ARHP Annual MeetingEducationgraduate medical educationmilestonesrheumatology

  • « Previous Page
  • 1
  • …
  • 167
  • 168
  • 169
  • 170
  • 171
  • …
  • 330
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences